Journal of the National Cancer Institute Advance Access originally published online on October 9, 2007
JNCI Journal of the National Cancer Institute 2007 99(20):1503-1504; doi:10.1093/jnci/djm195
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© Oxford University Press 2007.
NEWS |
UNFLAPPABLE PSA
Is An Improved PSA Screening Test In Sight?
| The first 10% of the full text of this article appears below. |
After decades of searching for a replacement for prostate-specific antigen (PSA) in prostate cancer screening, many researchers are once again examining variations on the long-beleaguered biomarker.
PSA has withstood years of skepticism from critics who blame it for the overdiagnosis and overtreatment of millions of men since it became the favorite prostate cancer screening test in the early 1990s. But PSA is staying put in the clinic. Now, instead of focusing on new markers of prostate cancer, many researchers are looking for ways to enhance PSA's predictive powers.
"PSA has been very effective in changing the landscape of prostate cancer, but it still has a number of significant limitations that need to be addressed," said Robert Getzenberg, Ph.D., director of research at Johns Hopkins University's
The Many Faces of PSA